What Happens to Addiction Cravings When You Stop Taking GLP-1 Drugs?

The Weight Loss Precedent

In the weight loss context, the data is clear: when people stop taking GLP-1 medications, appetite returns. A study following participants from the STEP 1 trial found that one year after discontinuing semaglutide, people had regained approximately two-thirds of the weight they had lost. The "food noise" comes back. The hunger hormones normalize within four to six weeks. The metabolic benefits begin to reverse.

This established pattern raises an obvious and critical question for addiction: if these drugs are dampening craving through the same dopamine-modulating mechanism that quiets food noise, will "drug noise" return just as reliably when the medication stops?

What Researchers Say

Dr. Ziyad Al-Aly, the WashU researcher behind the 606,434-veteran BMJ study, addressed this directly in a widely cited essay. He noted that many people who take GLP-1 drugs for obesity or diabetes discontinue them, and their appetite typically returns along with the weight they lost.

"Whether the same rebound would occur with addiction, and what it would mean for someone in recovery to face the roar of craving again, is unknown," he wrote. "Nor is it clear whether the benefits persist over years of continuous use, or whether the brain adapts in ways that dampen those effects."

This is a critical gap in the evidence. None of the major addiction studies — not the Lancet trial, not the WashU BMJ study, not the JAMA observational analyses — included follow-up data on what happened after participants stopped taking GLP-1 medications.

Why This Question Is So Important

The implications for addiction treatment are fundamentally different from weight management. If someone regains weight after stopping a GLP-1, the consequence is metabolic — real and important, but gradual and manageable. If someone's addiction cravings return suddenly after discontinuation, the consequences could be immediately life-threatening — particularly for opioids, where a period of reduced use lowers tolerance, making a return to previous dosing levels potentially fatal.

This creates a clinical dilemma: if GLP-1 medications prove effective for addiction but require indefinite use to maintain benefit, the cost, supply, and access implications become enormous. Current list prices for GLP-1 medications exceed $1,000 per month without insurance. For a condition that disproportionately affects populations with limited healthcare access, the economics are daunting.

One Hopeful Distinction

There is a theoretical reason to hope that craving rebound might be less severe than appetite rebound. Stanford addiction psychiatrist Dr. Anna Lembke has noted that GLP-1 medications are not themselves addictive and do not trigger withdrawal when discontinued. The rebound of appetite is driven by the restoration of hormonal signaling (ghrelin, leptin) to pre-treatment levels — a purely physiological process.

Addiction craving, while also biological, has a cognitive and contextual component that appetite for food does not. If GLP-1 medications, used in combination with therapy, help people build new behavioral patterns and break cue-substance associations during the treatment period, some of that benefit might persist after discontinuation — even if the raw craving drive returns.

This is speculative, however. The only way to know is through clinical trials that include post-discontinuation follow-up, and those trials are only now getting underway.

The Motivation Question

There's a related concern that extends beyond craving rebound. Because GLP-1 drugs modulate the brain's reward circuitry — the same system that governs not just craving but everyday motivation — prolonged use could theoretically dampen motivational drive in some people. Whether that might affect initiative, creative pursuits, social engagement, or job performance remains an open question.

This concern is distinct from anhedonia (inability to feel pleasure), which has not been widely reported among GLP-1 users. But the distinction between reduced "wanting" and reduced "liking" — which preclinical evidence suggests GLP-1 agonists primarily affect the former — needs rigorous human study over longer time horizons than any current trial provides.